Accessibility Menu
Autonomix Medical logo

Autonomix Medical(NASDAQ) AMIX

Market Cap$1.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-100%
5 YearN/A
1 Year-90%
1 Month-51%
$2.80
-4.11%
-0.12Today
Autonomix Medical last closing stock price
MetricPriceDate
Last closeUSD 2.792026-07-27
Autonomix Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-34.04%USD 4.232026-07-20
1 month-51.22%USD 5.722026-06-26
3 month-64.47%USD 7.852026-04-28
Year to date-75.84%USD 11.552025-12-31
1 year-90.44%USD 29.192025-07-25
Since inception-99.86%USD 2,129.402024-01-29

Autonomix Medical Financials at a Glance

Market Cap

$1.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$16.72M

EPS (TTM)

-$64.03

P/E Ratio

-0.05

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$2.80

Volume

3,231

Open

$2.95

Previous Close

$2.80

Daily Range

$2.72 - $3.10

52-Week Range

$2.65 - $32.55

Estimated Earnings Date

Aug 12, 2026

AMIX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Autonomix Medical

Autonomix develops medical devices to help doctors treat nerve-related pain. Its main system detects and treats nerve signals linked to cancer pain. The technology aims to reduce pain for patients with hard-to-treat conditions.

Gadgets That Listen: Products and Services

  • Catheter-Based Sensing System: Detects nerve signals in real time for pain management. (0% of revenue; pre-revenue)
  • Radiofrequency Ablation Platform: Treats pain by disrupting nerve signals using heat. (0% of revenue; pre-revenue)
  • Integrated Diagnostic and Therapy Device: Combines signal detection and treatment in one tool for doctors. (0% of revenue; pre-revenue)
  • Licensed RF Generator: Uses technology from RF Innovations for pain ablation, excluding spine pain. (0% of revenue; pre-revenue)

Plot Twists: Growth and Expansion

  • Licensed Apex 6 RF Generator from RF Innovations in July 2024.
  • Completed first human study for pancreatic cancer pain in 2025.
  • Launched second study in 2025 to target more cancer types and earlier-stage patients.
  • Strengthened intellectual property with two new U.S. patents in 2025.
  • Raised capital through public offering and warrant exercises in 2024 and 2025.

Why Autonomix Is a Bit Different

Autonomix’s system detects weak nerve signals that standard devices miss. Its device processes signals directly on the catheter, reducing noise. The company holds patents for its unique nerve-mapping and ablation technologies.

Five Things You Need to Know

  • No revenue reported for QQ2 2026, QQ2 2025, or QQ2 2024.
  • Net loss was $8 million in QQ2 2026, down 165.7% from QQ2 2025.
  • Cash flow from operations was negative $3 million in QQ2 2026, down 67.2% year-over-year.
  • Cash and equivalents were $8.6 million as of June 30, 2025.

Bottom Line

Autonomix remains in early development, focusing on nerve pain devices. The company faces funding and regulatory hurdles as it works toward commercialization.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

11

CEO

Bradley A. Hauser

Website

autonomix.com

Headquarters

The Woodlands, TX 77380, US

AMIX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-239.36%

Return on Capital

-288.96%

Return on Assets

-219.93%

Earnings Yield

-20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

543.30K

Volume

3.23K

Avg. Volume

239.01K

Financials (TTM)

Gross Profit

-$3.00K

Operating Income

-$17.04M

EBITDA

-$16.77M

Operating Cash Flow

-$11.13M

Capital Expenditure

-$10.00K

Free Cash Flow

-$11.14M

Cash & ST Invst.

$7.00M

Total Debt

$0.00

Autonomix Medical Performance Analysis

Autonomix Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 0N/A
Autonomix Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30N/A
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Autonomix Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -44.48-84.5%
20242024-03-31USD -343.78672.9%
20252025-03-31USD -135.65-60.5%
20262026-03-31USD -48.64-64.1%
Autonomix Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3040.9%
Q22025-09-30-29.0%
Q32025-12-3173.9%
Q42026-03-3136.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$3.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$158.64K

N/A

Employees

10

N/A

Net Income

-$2.67M

+16.5%

EBITDA

-$2.73M

+11.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$7.00M

-23.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.20%

N/A

Return on Invested Capital

-2.89%

N/A

Free Cash Flow

-$2.90M

-15.2%

Operating Cash Flow

-$2.89M

-15.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NAOVNanoVibronix, Inc.
$1.90+1.06%
BBLGBone Biologics Corporation
$1.03-4.21%
VEROVenus Concept Inc.
$0.31+2.64%
DHAIDIH Holding US, Inc.
$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About AMIX

What is the current price of Autonomix Medical?

Autonomix Medical is trading at $2.80 per share.

What is the 52-week range for Autonomix Medical?

Over the past 52 weeks, Autonomix Medical has traded between $2.65 and $32.55.

How much debt does Autonomix Medical have?

As of the most recent reporting period, Autonomix Medical reported total debt of $0.00.

How much cash does Autonomix Medical have on hand?

Autonomix Medical reported $7.00M in cash and cash equivalents in its most recent financial results.

What is Autonomix Medical’s dividend yield?

Autonomix Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services